Skip to main content
Erschienen in: Supportive Care in Cancer 6/2010

01.06.2010 | Special Article

An oral history of MASCC, its origin and development from MASCC's beginnings to 2009

verfasst von: Cynthia N. Rittenberg, Judith L. Johnson, Gerald M. Kuncio

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This paper presents an oral history from the mid-1980s to 2009 of the start and evolution of the Multinational Association of Supportive Care in Cancer (MASCC) as seen through the recollections of the founders and early leaders. The growth of the supportive cancer care movement and MASCC’s contribution to oncology supportive care is described.

Discussion

As science was making progress towards better cancer treatment, a group of professionals began to research ways to prevent or mitigate the symptoms and side effects that accompany the disease and its treatments. Joining forces, they created an international, multidisciplinary organization to address and promulgate evidence-based practices of cancer supportive care. Through annual international scientific symposia, a peer-reviewed journal, an accessible website, and study group projects such as guidelines and tools, MASCC is accomplishing its mission.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Senn HJ (1993) How “supportive” is yet another international oncology journal? Support Care Cancer 1(1):1CrossRef Senn HJ (1993) How “supportive” is yet another international oncology journal? Support Care Cancer 1(1):1CrossRef
2.
3.
Zurück zum Zitat Senn HJ, Glaus A (1987) Supportive care in cancer recent results in cancer research. Springer, Heidelberg Senn HJ, Glaus A (1987) Supportive care in cancer recent results in cancer research. Springer, Heidelberg
4.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051PubMed
5.
Zurück zum Zitat Ballatori E, Roila F, De Angelis V, Ciccarese G, Palladino MA, Tonato M, Del Favero A, Herrstedt J, Dicato M, Du Bois A, Hesketh P, Kris M, Gralla RJ (1997) Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Support Care Cancer 5:269–273CrossRefPubMed Ballatori E, Roila F, De Angelis V, Ciccarese G, Palladino MA, Tonato M, Del Favero A, Herrstedt J, Dicato M, Du Bois A, Hesketh P, Kris M, Gralla RJ (1997) Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Support Care Cancer 5:269–273CrossRefPubMed
6.
Zurück zum Zitat Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRef Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRef
9.
Zurück zum Zitat Gralla RJ, Roila F, Tonato M (2005) The 2004 Perugia antiemetic consensus guideline process: methods, procedures and participants. Support Care Cancer 13(2):77–79CrossRefPubMed Gralla RJ, Roila F, Tonato M (2005) The 2004 Perugia antiemetic consensus guideline process: methods, procedures and participants. Support Care Cancer 13(2):77–79CrossRefPubMed
10.
Zurück zum Zitat Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, duBois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 13(2):80–84CrossRefPubMed Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, duBois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 13(2):80–84CrossRefPubMed
11.
Zurück zum Zitat Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96CrossRefPubMed Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96CrossRefPubMed
12.
Zurück zum Zitat Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):97–103CrossRefPubMed Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C, Dicato M (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):97–103CrossRefPubMed
13.
Zurück zum Zitat Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104–108CrossRefPubMed Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104–108CrossRefPubMed
14.
Zurück zum Zitat Tonato M, Clark-Snow RA, Osoba D, Del Favero A, Ballatori E, Borjeson S (2005) Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13(2):109–111CrossRefPubMed Tonato M, Clark-Snow RA, Osoba D, Del Favero A, Ballatori E, Borjeson S (2005) Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer 13(2):109–111CrossRefPubMed
15.
Zurück zum Zitat Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13(2):112–116CrossRefPubMed Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C, Aapro M (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13(2):112–116CrossRefPubMed
16.
Zurück zum Zitat Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13(2):117–121CrossRefPubMed Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13(2):117–121CrossRefPubMed
17.
Zurück zum Zitat Feyer P, Maranzano E, Molassiotis A, Clark-Snow RA, Roila F, Warr D, Olver I (2005) Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer 13(2):122–128CrossRefPubMed Feyer P, Maranzano E, Molassiotis A, Clark-Snow RA, Roila F, Warr D, Olver I (2005) Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer 13(2):122–128CrossRefPubMed
18.
Zurück zum Zitat Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow RA, Warr D, Molassiotis A (2005) Antiemetics in children receiving chemotherapy. Support Care Cancer 13(2):129–131CrossRefPubMed Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow RA, Warr D, Molassiotis A (2005) Antiemetics in children receiving chemotherapy. Support Care Cancer 13(2):129–131CrossRefPubMed
19.
Zurück zum Zitat Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage 34(2):148–159CrossRefPubMed Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage 34(2):148–159CrossRefPubMed
20.
Zurück zum Zitat Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046CrossRefPubMed
21.
Zurück zum Zitat Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMed Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE, for the Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMed
22.
Zurück zum Zitat Kav S, Bostanci H (2005) Nurses attendance of patient education and follow-up for oral chemotherapy treatment in Turkey. Support Care Cancer 13(6):45 Kav S, Bostanci H (2005) Nurses attendance of patient education and follow-up for oral chemotherapy treatment in Turkey. Support Care Cancer 13(6):45
23.
Zurück zum Zitat Kav S, Johnson J, Rittenberg C, Fernandez-Ortega P, Suominen T, Olsen PR, Patiraki E, Porock D, Dahler A, Toliusiene J, Tadic D, Pittayapan P, Roy V, Wang Q, Colak M, Saca-Hazboun H, Makumi D, Dadmon I, Ben Ami S, Anderson E, Clark-Snow R (2008) Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 16(9):1075–1083CrossRefPubMed Kav S, Johnson J, Rittenberg C, Fernandez-Ortega P, Suominen T, Olsen PR, Patiraki E, Porock D, Dahler A, Toliusiene J, Tadic D, Pittayapan P, Roy V, Wang Q, Colak M, Saca-Hazboun H, Makumi D, Dadmon I, Ben Ami S, Anderson E, Clark-Snow R (2008) Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey. Support Care Cancer 16(9):1075–1083CrossRefPubMed
24.
Zurück zum Zitat Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2009) Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer. doi:10.1007/s00520-009-0692-5 Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C (2009) Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer. doi:10.​1007/​s00520-009-0692-5
25.
Zurück zum Zitat Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522 Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522
Metadaten
Titel
An oral history of MASCC, its origin and development from MASCC's beginnings to 2009
verfasst von
Cynthia N. Rittenberg
Judith L. Johnson
Gerald M. Kuncio
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0830-0

Weitere Artikel der Ausgabe 6/2010

Supportive Care in Cancer 6/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.